Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Gore, M; Szczylik, C; Porta, C; Bracarda, S; Bjarnason, G; Oudard, S; Lee, S; Haanen, J; Castellano, D; Vrdoljak, E; Schöffski, P; Mainwaring, P; Hawkins, Robert E; Crinò, L; Kim, T; Carteni, G; Eberhardt, W; Zhang, K; Fly, K; Matczak, E; Lechuga, M; Hariharan, S; Bukowski, R

Issue Date

2015-06-30

Metadata

Abstract

We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.

Citation

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. 2015, 113 (1):12-9 Br J Cancer

Journal

British Journal of Cancer

URI

http://hdl.handle.net/10541/561255

DOI

10.1038/bjc.2015.196

PubMed ID

26086878

Type

Article

Language

ISSN

1532-1827

Collections

All Paterson Institute for Cancer Research